Nasdaq · UTHR
United Therapeutics Corporation (UTHR)
$541.51+$1.48 (+0.27%)as of 4:00 PM ET Thu 15 Oct
Live quote as of 4:00 PM ET Thu 15 Oct · previous close $540.03 · source: Finnhub
Quarterly revenue
$783.3M
-1.9% vs. a year earlier · Quarter ended 30 Jun 2026
YTD +11.1%1M +8.6%Mkt cap $23.2B52-wk range $415.34–$596.76
What happened
- United Therapeutics closed at $541.51 on Thursday, 15 October, up 0.27%. It is up 11.1% this year, 9.3% below its 52-week closing high.
- Its latest reported quarter (quarter ended 30 Jun 2026) showed revenue of $783.3M, down 1% from $798.6M, and net income of $333.0M.
- Its most recent 8-K, filed 8 Sep 2026, signed a material agreement and published a Regulation FD disclosure.
- Next earnings: Wednesday, 4 November (estimated date); consensus EPS $6.25.
UTHR price chart
$500$550AugSepOct$542
$500$550$600MayJunJulAugSepOct$542
$500$600NovDecJan '26FebMarAprMayJunJulAugSepOct$542
Key numbers
| Revenue (latest quarter) | $783.3M-1.9% year over year · Quarter ended 30 Jun 2026 |
|---|---|
| Revenue (last 4 quarters) | $3.2B |
| Net income | $333.0Mup 7% from $309.5M a year earlier |
| Diluted EPS | $7.27vs. $6.41 a year earlier |
| Operating margin | 42.2% |
| Cash & equivalents | $1.8Bat 30 Jun 2026 |
| Market cap | $23.23BNasdaq |
| 52-week closing range | $415.34 – $596.76high on 6 May 2026 |
| Latest periodic report | 10-Qfiled 5 Aug 2026 · period 30 Jun 2026 |
| Next earnings | 4 Nov 2026*estimated (Zacks via Nasdaq) |
| Industry | Biotechnology: Pharmaceutical PreparationsHealth Care |
Revenue by quarter
In the filing
United Therapeutics's latest 10-Q, filed 5 August 2026 for the period ended 30 June 2026, reported revenue of $783.3M, down 1% from $798.6M a year earlier, and 0.2% more than the previous quarter.
Net income was $333.0M (up from $309.5M). Diluted EPS was $7.27, against $6.41 a year before. Operating margin was 42.2%. Cash and equivalents stood at $1.8B on 30 Jun 2026.
Latest 8-K · 8 Sep 2026
United Therapeutics signed a material agreement and published a Regulation FD disclosure. Read on SEC.gov
Earnings vs. expectations
Reported EPS Consensus
Recent SEC filings
| Date | Form | What it is |
|---|---|---|
| 8 Sep 2026 | 8-K | Current report: signed a material agreement and published a Regulation FD disclosure |
| 5 Aug 2026 | 8-K | Current report: reported results of operations |
| 5 Aug 2026 | 10-Q | Quarterly report |
| 23 Jul 2026 | 8-K | Current report: reported a director or officer change and published a Regulation FD disclosure |
| 29 Jun 2026 | 8-K | Current report: reported a director or officer change and reported shareholder vote results |
| 6 May 2026 | 8-K | Current report: reported results of operations |
| 6 May 2026 | 10-Q | Quarterly report |
| 29 Apr 2026 | DEF 14A | Proxy statement |
The daily filings brief
Before the US open: the movers, the SEC filings and the earnings that matter. Free, one short email per US trading day.
We only use your email to send the brief.